ArticleJTO clinical and research reports2026
Definitive Radiotherapy With or Without Chemotherapy After Planned Neoadjuvant Chemoimmunotherapy in Stages II to III NSCLC: An International Multicenter Retrospective Study.
Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Caution Against Uncritical Adoption of Neoadjuvant Chemoimmunotherapy Followed by Definitive Radiotherapy in Stages II to III NSCLC: In Response to Adib et al.JTO clinical and research reports · 2026Article
- In Response.JTO clinical and research reports · 2026Article
- Real-world outcomes of unresected non-small cell lung cancer following neoadjuvant chemoimmunotherapy.General thoracic and cardiovascular surgery · 2026Article
- Progress in Designing Cytokine Antagonist Antibodies for Cancer Therapy.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Approximately 15% to 20% of patients with resectable NSCLC receiving neoadjuvant chemoimmunotherapy on clinical trials cannot proceed to surgery due to disease progression, toxicity, or medical contraindications. The safety and efficacy of definitive radiotherapy (RT) in this population are uncertain. Methods: We performed an international multicenter (13 institutions) retrospective study of patients with stages II to III NSCLC who received more than or equal to 2 cycles of neoadjuvant platinum-based chemoimmunotherapy followed by definitive RT instead of planned surgery. The primary end point was pneumonitis incidence; secondary end points included progression-free survival (PFS), overall survival (OS), and treatment-related adverse events. Results: We identified 57 patients, 54 (90%) of whom had stage III NSCLC. The most common reasons for definitive RT were surgical resectability (n = 38, 67%), followed by new-onset medical contraindications (n = 15, 26%), patient preference (n=3, 5%), and complete radiographic response (n = 1, 2%). Pneumonitis occurred in 10 patients (18%), including six grade 3 to 4 events (10.5%) and one grade 5 event (2%), with no differences based on concurrent chemotherapy or consolidation systemic therapy. Most patients (n = 36, 63%) achieved partial radiographic response to neoadjuvant therapy. With median follow-up of 17 months, median PFS was 16.1 months (95% confidence interval [CI] 12.2-not reached [NR]) and median OS was not reached (interquartile range 20.5-NR). One-year OS rate was 81% (95% CI 70%-94%). PFS was longer in patients undergoing RT for medical contraindications versus surgical resectability (30.3 [95% CI 16.1-NR] versus 12.2 [95% CI 7.6-NR] mo; Conclusion: Definitive RT after neoadjuvant chemoimmunotherapy demonstrates promising effectiveness and safety in patients unable to undergo planned surgery. Prospective studies should focus on adaptive RT approaches and biomarker development to improve outcomes in this challenging population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.